Keynote Speakers

john maraganore, phd

Dr. John Maraganore is the CEO and Principal of JMM Innovations, LLC, committed to the advancement of biomedical innovation to patients.

Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first five RNAi therapeutics, creating a whole new class of medicines. At Alnylam, he built one of the biotech industry’s most successful companies with over $25B in market capitalization during his tenure.

Prior to Alnylam, he held scientific and business leadership roles at Millennium Pharmaceuticals, Inc., Biogen, Inc. - where he invented and led the discovery and development of ANGIOMAX® (bivalirudin), ZymoGenetics, Inc., and the Upjohn Company.  

Dr. Maraganore currently serves as a Venture Partner and Advisor with a number of investment firms including Arch Ventures, Atlas Ventures, Blackstone, and RTW Investments. He is a member of the Board of Directors of multiple publicly traded companies, including Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics, and Takeda Pharmaceuticals. He is also on the Board of a number of private companies including Aera Therapeutics, Aitia, Hemab Therapeutics, and Orbital Therapeutics. Maraganore also serves as a strategic advisor to other public and private biotechnology companies, and serves on the Boards or Advisory Boards of a number of non-profit organizations. Finally, Dr. Maraganore is on the Board of the Biotechnology Innovation Organization, or “BIO,” where he was Chair from 2017-2019 and is Chair Emeritus. 

Dr. Maraganore received his B.A., M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago.